Shandong Wohua Pharmaceutical Beheer

Beheer criteriumcontroles 3/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Yingzi Zeng

Algemeen directeur

CN¥552.0k

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	4.9yrs
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	5.3yrs
Gemiddelde ambtstermijn bestuur	4.8yrs

Recente managementupdates

Recent updates

Shandong Wohua Pharmaceutical's (SZSE:002107) Conservative Accounting Might Explain Soft Earnings

Apr 05

Subdued Growth No Barrier To Shandong Wohua Pharmaceutical Co., Ltd. (SZSE:002107) With Shares Advancing 28%

Mar 08

CEO

Yingzi Zeng (61 yo)

4.9yrs

Tenure

CN¥552,000

Compensatie

Ms. Yingzi Zeng is President of Shandong Wohua Pharmaceutical Co., Ltd. from December 05, 2019.

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Yingzi Zeng	President	4.9yrs	CN¥552.00k	geen gegevens
Caixia Zhao	Board Secretary & Vice Chairman	5.8yrs	CN¥957.60k	0.0097% CN¥ 267.9k
Jiong Wang	CFO, VP & In Charge of Accounting	13.9yrs	CN¥723.20k	geen gegevens
Qian Yang	Deputy General Manager	2.8yrs	CN¥1.71m	geen gegevens

5.3yrs

Gemiddelde duur

55.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 002107 is doorgewinterd en ervaren (gemiddelde ambtstermijn van 5.3 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Caixia Zhao	Board Secretary & Vice Chairman	5.8yrs	CN¥957.60k	0.0097% CN¥ 267.9k
Bing Xian Zhao	Chairman of the Board	18.6yrs	geen gegevens	geen gegevens
Ge Zhang	Director	15.4yrs	CN¥957.60k	1.74% CN¥ 48.4m
Shengting Li	Non-Independent Director	2.8yrs	CN¥684.00k	geen gegevens
Wenjun Yin	Non-Employee Chairman of the Board of Supervisors	7.5yrs	geen gegevens	geen gegevens
Bofang Liu	Non-Employee Supervisor	5.8yrs	geen gegevens	geen gegevens
Lijuan Liu	Employee Representative Supervisor	5.8yrs	geen gegevens	geen gegevens
Wanhui Zhou	Supervisor	3.8yrs	geen gegevens	0.0016% CN¥ 45.8k
Yong Chen	Non-Independent Director	2.8yrs	CN¥387.50k	geen gegevens
Mingqin Gao	Independent Director	2.8yrs	CN¥120.00k	geen gegevens
Junli Yu	Independent Director	2.8yrs	CN¥120.00k	geen gegevens
Yuesheng Wang	Independent Director	1.6yrs	CN¥70.00k	geen gegevens

4.8yrs

Gemiddelde duur

55yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 002107 wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.8 jaar).

Shandong Wohua Pharmaceutical Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Shandong Wohua Pharmaceutical Co., Ltd., Annual General Meeting, Apr 19, 2024

High number of new directors

High number of new directors

High number of new directors

High number of new directors

Shandong Wohua Pharmaceutical Co., Ltd. Announces Executive Appointments

Recent updates

Third quarter 2024 earnings released: EPS: CN¥0.019 (vs CN¥0.042 in 3Q 2023)

Shandong Wohua Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Oct 26, 2024

Investor sentiment improves as stock rises 19%

Second quarter 2024 earnings released: EPS: CN¥0.002 (vs CN¥0.019 in 2Q 2023)

Now 21% undervalued after recent price drop

Shandong Wohua Pharmaceutical Co., Ltd. to Report First Half, 2024 Results on Aug 03, 2024

Now 21% undervalued after recent price drop

Now 22% undervalued after recent price drop

First quarter 2024 earnings released: EPS: CN¥0.02 (vs CN¥0.04 in 1Q 2023)

Investor sentiment deteriorates as stock falls 21%

New major risk - Dividend sustainability

Shandong Wohua Pharmaceutical's (SZSE:002107) Conservative Accounting Might Explain Soft Earnings

Full year 2023 earnings released: EPS: CN¥0.10 (vs CN¥0.19 in FY 2022)

Shandong Wohua Pharmaceutical Co., Ltd., Annual General Meeting, Apr 19, 2024

Now 22% overvalued

Subdued Growth No Barrier To Shandong Wohua Pharmaceutical Co., Ltd. (SZSE:002107) With Shares Advancing 28%

Now 23% overvalued

Investor sentiment improves as stock rises 19%

Investor sentiment deteriorates as stock falls 20%

Shandong Wohua Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Mar 30, 2024

Third quarter 2023 earnings released: EPS: CN¥0.042 (vs CN¥0.04 in 3Q 2022)

New minor risk - Profit margin trend

Second quarter 2023 earnings released: EPS: CN¥0.019 (vs CN¥0.05 in 2Q 2022)

Shandong Wohua Pharmaceutical Co., Ltd. to Report First Half, 2023 Results on Jul 29, 2023

Full year 2022 earnings released: EPS: CN¥0.19 (vs CN¥0.28 in FY 2021)

High number of new directors

Third quarter 2022 earnings released: EPS: CN¥0.04 (vs CN¥0.06 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.05 (vs CN¥0.09 in 2Q 2021)

Now 21% undervalued after recent price drop

High number of new directors

First quarter 2022 earnings released: EPS: CN¥0.05 (vs CN¥0.09 in 1Q 2021)

High number of new directors

High number of new directors

Shandong Wohua Pharmaceutical Co., Ltd. Announces Executive Appointments

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.06 (vs CN¥0.09 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.09 (vs CN¥0.081 in 2Q 2020)

First quarter 2021 earnings released: EPS CN¥0.09 (vs CN¥0.075 in 1Q 2020)

New 90-day low: CN¥7.39

New 90-day low: CN¥7.55

Shandong Wohua Pharmaceutical Co., Ltd., Annual General Meeting, Feb 19, 2021

Full year 2020 earnings released: EPS CN¥0.31

Full year 2020 earnings released: EPS CN¥0.31

Investor sentiment improved over the past week

New 90-day low: CN¥8.10

New 90-day low: CN¥8.90

Third quarter earnings released

Shandong Wohua Pharmaceutical Co., Ltd. to Report Q3, 2020 Results on Oct 16, 2020

New 90-day low: CN¥9.24

New 90-day low - CN¥10.07

Shandong Wohua Pharmaceutical Co., Ltd. to Report First Half, 2020 Results on Jul 16, 2020

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd